Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can this pill tame the nausea from popular Weight-Loss shots?

NCT ID NCT06500429

Symptom relief Sponsor: Neurogastrx, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested whether an oral drug called NG101 can reduce gastrointestinal side effects (like nausea and vomiting) caused by GLP-1 weight-loss medications such as semaglutide. 120 healthy adults with a BMI between 22 and 35 took either NG101 or a placebo for five days, and received a single injection of semaglutide on day two. Researchers measured how long and how severe stomach-related side effects lasted.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NG101 (metopimazine mesylate)
What this could lead to
If it works, NG101 could become a pill that helps people tolerate common GLP-1 drugs by reducing nausea, vomiting, and other stomach issues.
What could go wrong
This is a small, early proof-of-concept study in healthy volunteers, not patients. The drug may not work as well in real-world use or could have its own side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

120 people

The number who actually took part.

Started

Jun 2024

Finished

Sep 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy adult * Male or female * BMI between 22 - 35 kg/m2 at screening Exclusion Criteria: * Presence or history of illness that might confound the results of the study or pose an - * History of presence of gastroparesis, gallbladder disease, acute or chronic pancreatitis, or surgery of the abdomen * History or presence of Type 1 or Type 2 diabetes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy Overweight and obesity

Contacts and locations

Locations

  • Celerion

    Tempe, Arizona, 85283, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.